A network meta-analysis examined 2,585 patients with liver metastatic uveal melanoma to compare different treatments. The study looked at tebentafusp, immune checkpoint inhibitors, targeted therapy, chemotherapy, and liver-directed options.
The analysis found that liver-directed therapy combined with immune checkpoint inhibitors provided the most effective results for both overall survival and progression-free survival. Tebentafusp showed the second-best overall survival but had the worst progression-free survival compared to other options. Immune checkpoint inhibitors alone were inferior to tebentafusp for overall survival but showed better progression-free survival than tebentafusp.
Regional liver-directed therapy demonstrated more favorable outcomes than conventional systemic chemotherapy, targeted therapy, or their combination. The study noted that emerging immunotherapies and novel targeted agents could not be included because comparative trials were missing or ongoing. Future studies incorporating these new therapies are warranted. Safety data such as adverse events were not reported in the available information.
